Antithrombotic management during percutaneous mechanical circulatory support: defining the status quo, before agreeing quo vadis
European Heart Journal: Acute Cardiovascular Care · 2024
DOI: 10.1093/ehjacc/zuae056 ↗Kurz gefasst
Editorial in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2024. Verfasst von Diana A Gorog und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, UK. Hauptthemen laut MEDLINE: Heart-Assist Devices, Fibrinolytic Agents. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
The incidence of cardiogenic shock (CS) is increasing1–3 and continues to carry a very high in-hospital mortality rate of 40–50%.4,5 Patients often present late and manifest already a downward haemodynamic spiral of progressive myocardial depression. Percutaneous temporary mechanical circulatory support (pMCS) devices, comprising mainly veno-arterial extracorporeal membrane oxygenation (V-A ECMO) and micro-axial pumps, when available, are increasingly used in an attempt to improve haemodynamic indices and survival in this high-risk group. However, the effectiveness of pMCS is encumbered by the double-edged sword of device-associated thrombotic complications, due mainly to platelet and contact pathway activation by the artificial circuit on the one hand, and the risk of major bleeding complications due to anticoagulation and shear-induced von Willebrand syndrome, on the other. In the real world, complications of pMCS tend to be higher than in carefully conducted clinical trials. However, even in the ECLS-SHOCK trial in patients with acute myocardial infarction (AMI) complicated by CS, nearly one in four patients receiving VA-ECMO experienced moderate-to-severe bleeding complications, compared with only 9.6% of those treated without MCS [relative risk (RR) 2.44; 95% confidence interval (CI), 1.50–3.95], with pMCS increasing the rate of vascular complications necessitating intervention (11.0% vs. 3.8%, RR 2.86; 95% CI, 1.31–6.25), as well as the rate of stroke or systemic embolization (3.8% vs. 2.9%, RR 1.33; 95% CI, 0.47–3.76).6 The recently published DanGer Shock trial, comparing the use of a micro-axial flow pump (Impella CP) against no pMCS in patients with AMI-related CS, showed that the use of a micro-axial flow pump led to a lower risk of all-cause death at 180 days.7 Whilst this will undoubtedly lead to an increase in the use of Impella support in these patients, the reported device-related complication rate is sobering, with the number needed to harm with micro-axial flow pump being only six patients. The composite safety endpoint occurred in 24% of patients in the micro-axial flow pump group and only 6.2% in the standard care group (RR 4.74; 95% CI, 2.36–9.55). The RR of the micro-axial flow pump support compared with standard care for the exploratory endpoints of moderate or severe bleeding was 2.06 (95% CI, 1.15–3.66), for limb ischaemia 5.15 (95% CI, 1.11 to 23.84), for renal replacement therapy 1.98 (95% CI, 1.27–3.09), and for stroke 3.9 vs. 2.3% (RR 1.75, 0.5–6.01). It is apparent that the delicate balance between bleeding and thrombosis in patients with CS treated with pMCS leads to a number of complications, which in part relate to the choice, intensity, and monitoring of antithrombotic therapy. Therefore, there is an important unmet need to optimize care to minimize these relatively frequent complications and improve outcomes in these patients. To do so, the first step is to actually understand the status quo: how are these patients currently managed in terms of (i) choice, intensity, and number of antithrombotic medications; (ii) monitoring the effectiveness of anticoagulation; (iii) monitoring for bleeding; and (iv) transfusion requirements. In this issue of the EHJ-ACVC, Vandenbriele, Van Edom, and colleagues publish the results of an international survey to address these important questions, under the auspices of the European Society of Cardiology.8 The online survey of antithrombotic practices and transfusion thresholds received feedback from 99 centres based across 26 European countries. The survey reveals very significant variation in antithrombotic practices, with only 40% of respondents having both an anticoagulation and transfusion protocol in their centre. This contrasts with Extracorporeal Life Support Organisation (ELSO) surveys on ECMO in 2013 and 2021, in predominantly paediatric and neonatal intensive care units, where 72% and 79% centres had both protocols.9,10 Notably, 72.4% of respondents adhered to locally established anticoagulation protocols, with unfractionated heparin (UFH) being the predominant anticoagulant (Impella 97.0% and V-A ECMO: 96.1%). Only a minority, 10.8% and 14.5%, respectively, utilized anti-factor-Xa assay with activated partial thromboplastin time in parallel for UFH monitoring during Impella and V-A ECMO support. Anticoagulant targets varied across institutions, as did the response to UFH target overshooting. Following an ACS presentation, even in patients who had not undergone percutaneous coronary intervention (PCI), 54.0% and 42.7% of respondents administered dual antiplatelet therapy (DAPT) during Impella and V-A ECMO support, increasing to 93.7% and 84.0% after PCI. The threshold for blood and platelet transfusion was also varied, and some 40% of respondents, despite the known high bleeding risk and the prevalence of DAPT use (in addition to UFH), would only give platelet transfusion if the platelet count fell below 40 × 109/L. The paper highlights three important areas for improvement: firstly, the lack of standardized protocols and targets when monitoring anticoagulant effect in patients on pMCS, in terms of the tests used (or available) and the frequency of monitoring, including the use of tests to detect bleeding; secondly, the lack of standardized protocols for antithrombotic medication, including lack of protocols for anticoagulant and antiplatelet therapy (including the use of single or dual antiplatelet therapy and its intensity). It would appear that many centres are directly translating ‘routine’ guidelines for antiplatelet medication in patients with ACS11 to this high-risk cohort, in which evidence for ‘triple therapy’ (combination of DAPT and anticoagulation) is lacking. Furthermore, since by definition, all patients on pMCS should be considered high bleeding risk, in all but the very highest ischaemic risk patients, the guidelines for ‘de-escalation’ to minimize the duration and intensity of antiplatelet therapy should be followed.12 We would advocate individual assessment of ischaemic risk in ACS patients that should take into account the nature and complexity of the coronary disease and the technical details of any recent revascularization, as well as concomitant ischaemic risk factors.12 Although not formally evaluated exclusively in the setting of CS, there is a growing body of data that de-escalation of DAPT intensity or duration can significantly reduce bleeding without increasing ischaemic risk.11,12 Finally, the wide variability in the approach to the management of blood and platelet transfusions is concerning and there is no reason why this should not be standardized. Whilst some recommendations have previously been proposed to mitigate against bleeding and ischaemic risks in this cohort,13–15 it is clear that these are not informing routine care. Furthermore, the management of such patients by a combination of specialists that include intensivists, interventional cardiologists, and the heart failure team, with or without expert haematology input, can result in differing expertise with possibly conflicting approaches to the management of antithrombotic therapy and transfusion thresholds. Since there is an absence of evidence base for treatment and monitoring of these patients, the first step is to agree to risk assess individual patients for the magnitude of bleeding and ischaemic risks, to agree on standardized pathways for monitoring and treatment, and then to work towards developing pathways to provide personalized care. Doctors Vandenbriele, Van Edom, and colleagues should be congratulated for this important work, which highlights the significant variation in clinical practice and is, hopefully, the first step in translating this into recommendations to standardize antithrombotic monitoring and treatment and minimize complications in this very high-risk group. None declared. No new data were generated or analysed in support of this research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, UK.
- Postgraduate Medical School, University of Hertfordshire, Hertfordshire, UK.
- Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
- Institute of Cardiometabolism and Nutrition, Sorbonne Université, INSERM Unité Mixte de Recherche (UMRS) 1166, Paris, France.
- Service de Médecine Intensive-Réanimation, Hôpital Pitié-Salpêtrière, Sorbonne Université Assistance Publique-Hôpitaux de Paris, Paris, France.
ORCID-Profile: Diana A Gorog
Zitieren
APA
Gorog, D. A., & Combes, A. (2024). Antithrombotic management during percutaneous mechanical circulatory support: defining the status quo, before agreeing quo vadis. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuae056
Vancouver
Gorog DA, Combes A. Antithrombotic management during percutaneous mechanical circulatory support: defining the status quo, before agreeing quo vadis. European Heart Journal: Acute Cardiovascular Care. 2024. doi:10.1093/ehjacc/zuae056
BibTeX
@article{Gorog2024,
author = {Gorog, Diana A and Combes, Alain},
title = {Antithrombotic management during percutaneous mechanical circulatory support: defining the status quo, before agreeing quo vadis},
journal = {European Heart Journal: Acute Cardiovascular Care},
year = {2024},
doi = {10.1093/ehjacc/zuae056}
}
EUVIMED